HUTCHMED (China) Limited (HCM)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

323.00p
   
  • Change Today:
    -1.00p
  • 52 Week High: 352.00p
  • 52 Week Low: 173.60p
  • Currency: UK Pounds
  • Shares Issued: 871.26m
  • Volume: 2,416
  • Market Cap: £2,814.16m
  • RiskGrade: 226

Director dealings: Chi-Med director's wife bags a bargain?

By Oliver Haill

Date: Tuesday 09 Aug 2016

LONDON (ShareCast) - (ShareCast News) - The wife of Hutchison China MediTech (Chi-Med) director Christopher Nash has swooped into the market to pick up a few of the company's shares a after hearing good reports on the China-based biopharma outfit's recent interim results and bulging drug pipeline.
Mrs Nash, wife of the company's senior independent non-executive director, snapped up 3,120 shares at the price of 1,900p and 42 at 1,899p last week, Chi-Med announced on Tuesday, to inflate the Nash household's ownership to 39,596 of the company's shares.

A week ago, Chi-Med's interim results showed group revenue up 27% to $104.5m but net income down to $0.5m due to a sharp increase in clinical investment as it funds the progress of seven drug candidates in 25 clinical trials, of which four are pivotal Phase III studies.

Through the coming three quarters, Chi-Med plans to publish proof-of-concept or pivotal trial data on four drug candidates.

Also, last Monday Chi-Med and FTSE 100 giant AstraZeneca announced an amendment to their 2011 global licensing, co-development, and commercialisation agreement regarding Chi-Med's savolitinib cancer treatment, which is currently undergoing trials for non-small cell lung cancer, kidney, gastric and colorectal cancers.

Chi-Med has now agreed contribute up to $50m over three years to the joint development costs of the global pivotal Phase III study in the c-Met gene affect on papillary renal cell carcinoma (PRCC).

Subject to approval in the PRCC indication, Chi-Med will receive a 5 percentage point increase in the global - excluding China - tiered royalty rate payable on savolitinib sales across all indications.

Top Director Buys

Hutchison China Meditech Ltd (HCM)
Director name: Nash,Christopher
Amount purchased: 3,120 @ 1,900.00p
Value: £59,280.00

Vitec Group (VTC)
Director name: Thomson,Caroline
Amount purchased: 8,407 @ 590.00p
Value: £49,601.30

Vitec Group (VTC)
Director name: Rollins,Mark
Amount purchased: 5,100 @ 590.00p
Value: £30,090.00

Verona Pharma (VRP)
Director name: Jan-Anders Karlsson,Sven
Amount purchased: 600,000 @ 3.25p
Value: £19,494.00

Elegant Hotels Group (EHG)
Director name: Adams,David
Amount purchased: 6,000 @ 63.50p
Value: £3,810.00

Hutchison China Meditech Ltd (HCM)
Director name: Nash,Christopher
Amount purchased: 42 @ 1,899.00p
Value: £797.58

Mj Gleeson (GLE)
Director name: Allanson ,Stefan
Amount purchased: 38 @ 509.75p
Value: £193.70

Rolls-royce Holdings (RR.)
Director name: Smith,David
Amount purchased: 20 @ 764.00p
Value: £152.80

Countrywide (CWD)
Director name: Platt,Alison
Amount purchased: 61 @ 248.50p
Value: £151.58

Countrywide (CWD)
Director name: Clarke,Jim
Amount purchased: 60 @ 248.50p
Value: £149.10

Rolls-royce Holdings (RR.)
Director name: Smith,Colin P
Amount purchased: 17 @ 764.00p
Value: £129.88

Interserve (IRV)
Director name: Haywood,Tim
Amount purchased: 40 @ 312.00p
Value: £124.80

Interserve (IRV)
Director name: Melizan,Bruce
Amount purchased: 40 @ 312.00p
Value: £124.80



Top Director Sells

Dignity (DTY)
Director name: Davies,Andrew
Amount sold: 32,405 @ 2,640.92p
Value: £855,788.97

Dignity (DTY)
Director name: Portman,Richard
Amount sold: 25,929 @ 2,680.00p
Value: £694,897.18

Dignity (DTY)
Director name: Whittern,Steve
Amount sold: 21,301 @ 2,634.00p
Value: £561,068.34

Nichols (NICL)
Director name: Millard ,Marnie
Amount sold: 8,254 @ 1,400.00p
Value: £115,556.00

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

HCM Market Data

Currency UK Pounds
Share Price 323.00p
Change Today -1.00p
% Change -0.31 %
52 Week High 352.00p
52 Week Low 173.60p
Volume 2,416
Shares Issued 871.26m
Market Cap £2,814.16m
RiskGrade 226

HCM Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
75.13% below the market average75.13% below the market average75.13% below the market average75.13% below the market average75.13% below the market average
60.78% below the sector average60.78% below the sector average60.78% below the sector average60.78% below the sector average60.78% below the sector average
Price Trend
78.92% above the market average78.92% above the market average78.92% above the market average78.92% above the market average78.92% above the market average
92.59% above the sector average92.59% above the sector average92.59% above the sector average92.59% above the sector average92.59% above the sector average
Income Not Available
Growth
67.71% above the market average67.71% above the market average67.71% above the market average67.71% above the market average67.71% above the market average
88.24% above the sector average88.24% above the sector average88.24% above the sector average88.24% above the sector average88.24% above the sector average

HCM Dividends

No dividends found

Trades for 20-May-2024

Time Volume / Share Price
10:05 1,562 @ 320.12p
10:04 1 @ 320.01p
09:44 157 @ 320.40p
09:02 96 @ 323.00p
08:57 154 @ 321.95p

HCM Key Personnel

Chair Dan Eldar
CEO Weiguo Su

Top of Page